Magdalena Hryhorowicz

Dr. Magdalena Hryhorowicz


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2016 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Open access
PDF file
MHMagdalena Hryhorowicz
Magdalena Hryhorowicz
DLDaniel Lipiński
Daniel Lipiński
Joanna ZeylandJoanna Zeyland
Joanna Zeyland
RSRyszard Slomski
Ryszard Slomski
CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated) adaptive immune systems constitute a bacterial defence against invading nucleic acids derived from bacteriophages or plasmids. This prokaryotic system was adapted in molecular biology and became one of the most powerful and versatile platforms for genome engineering. CRISPR/Cas9 is a simple and rapid tool which enables the efficient modification of endogenous genes in various species and cell types. Moreover, a modified version of the CRISPR/Cas9 system with transcriptional repressors or activators allows robust transcription repression or activation of target genes. The simplicity of CRISPR/Cas9 has resulted in the widespread use of this technology in many fields, including basic research, biotechnology and biomedicine.

11 July 2017 in Molecular Biotechnology
Verified
Journal Article
Open access
PDF file
MHMagdalena Hryhorowicz
Magdalena Hryhorowicz
Joanna ZeylandJoanna Zeyland
Joanna Zeyland
RSRyszard Slomski
Ryszard Slomski
DLDaniel Lipiński
Daniel Lipiński
The growing shortage of available organs is a major problem in transplantology. Thus, new and alternative sources of organs need to be found. One promising solution could be xenotransplantation, i.e., the use of animal cells, tissues and organs. The domestic pig is the optimum donor for such transplants. However, xenogeneic transplantation from pigs to humans involves high immune incompatibility and a complex rejection process. The rapid development of genetic engineering techniques enables genome modifications in pigs that reduce the cross-species immune barrier.

19 June 2020 in Genes
Verified
Journal Article
Open access
PDF file
MHMagdalena Hryhorowicz
Magdalena Hryhorowicz
DLDaniel Lipiński
Daniel Lipiński
SHSzymon Hryhorowicz
Szymon Hryhorowicz
ANAgnieszka Nowak-Terpiłowska
Agnieszka Nowak-Terpiłowska
NRNatalia Ryczek
Natalia Ryczek
Joanna ZeylandJoanna Zeyland
Joanna Zeyland
Progress in genetic engineering over the past few decades has made it possible to develop methods that have led to the production of transgenic animals. The development of transgenesis has created new directions in research and possibilities for its practical application. Generating transgenic animal species is not only aimed towards accelerating traditional breeding programs and improving animal health and the quality of animal products for consumption but can also be used in biomedicine. Animal studies are conducted to develop models used in gene function and regulation research and the genetic determinants of certain human diseases. Another direction of research, described in this review, focuses on the use of transgenic animals as a source of high-quality biopharmaceuticals, such as recombinant proteins. The further aspect discussed is the use of genetically modified animals as a source of cells, tissues, and organs for transplantation into human recipients, i.e., xenotransplantation. Numerous studies have shown that the pig (Sus scrofa domestica) is the most suitable species both as a research model for human diseases and as an optimal organ donor for xenotransplantation. Short pregnancy, short generation interval, and high litter size make the production of transgenic pigs less time-consuming in comparison with other livestock species This review describes genetically modified pigs used for biomedical research and the future challenges and perspectives for the use of the swine animal models.

Verified
Journal Article
Open access
PDF file
MHMagdalena Hryhorowicz
Magdalena Hryhorowicz
DLDaniel Lipiński
Daniel Lipiński
Joanna ZeylandJoanna Zeyland
Joanna Zeyland
The bacteria-derived CRISPR/Cas (an acronym for regularly interspaced short palindromic repeats/CRISPR-associated protein) system is currently the most widely used, versatile, and convenient tool for genome engineering. CRISPR/Cas-based technologies have been applied to disease modeling, gene therapies, transcriptional modulation, and diagnostics. Nevertheless, some challenges remain, such as the risk of immunological reactions or off-target effects. To overcome these problems, many new methods and CRISPR/Cas-based tools have been developed. In this review, we describe the current classification of CRISPR systems and new precise genome-editing technologies, summarize the latest applications of this technique in several fields of research, and, finally, discuss CRISPR/Cas system limitations, ethical issues, and challenges.

1 November 2016 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
MFMonika Fraczek
Monika Fraczek
MHMagdalena Hryhorowicz
Magdalena Hryhorowicz
KGKamil Gill
Kamil Gill
MZMarta Zarzycka
Marta Zarzycka
DGDariusz Gaczarzewicz
Dariusz Gaczarzewicz
Maciej KurpiszMaciej Kurpisz
Maciej Kurpisz

Verified
Journal Article
Open access
PDF file
NRNatalia Ryczek
Natalia Ryczek
MHMagdalena Hryhorowicz
Magdalena Hryhorowicz
Joanna ZeylandJoanna Zeyland
Joanna Zeyland
DLDaniel Lipiński
Daniel Lipiński
RSRyszard Slomski
Ryszard Slomski
CRISPR/Cas (clustered regularly interspaced short palindromic repeats linked to Cas nuclease) technology has revolutionized many aspects of genetic engineering research. Thanks to it, it became possible to study the functions and mechanisms of biology with greater precision, as well as to obtain genetically modified organisms, both prokaryotic and eukaryotic. The changes introduced by the CRISPR/Cas system are based on the repair paths of the single or double strand DNA breaks that cause insertions, deletions, or precise integrations of donor DNA. These changes are crucial for many fields of science, one of which is the use of animals (pigs) as a reservoir of tissues and organs for xenotransplantation into humans. Non-genetically modified animals cannot be used to save human life and health due to acute immunological reactions resulting from the phylogenetic distance of these two species. This review is intended to collect and summarize the advantages as well as achievements of the CRISPR/Cas system in pig-to-human xenotransplantation research. In addition, it demonstrates barriers and limitations that require careful evaluation before attempting to experiment with this technology.